Compare Twist Bioscience Corp (TWST) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Exxon Mobil Corporation — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Exxon Mobil Corporation trades at $164.43 (market cap $660.62B). The key difference: Exxon Mobil Corporation is far larger — about 78.5× Twist Bioscience Corp's market cap, and Exxon Mobil Corporation pays a 2.56% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | XOM | |
|---|---|---|
Market Cap | $8.42B | $660.62B |
Sector | Health | Energy |
52-Week High | $153.10 | $171.52 |
52-Week Low | $24.16 | $110.64 |
Enterprise Value | $8.35B | $692.40B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
ExxonMobil (XOM) trades at $164.26, up 3.01% today, with a neutral technical signal and bullish moving averages. The stock shows solid profitability with a 9.07% net margin and 12.55% ROE, though revenue and net income have declined from 2022 peaks. Recent earnings beat estimates in two of the last three quarters, with Q3 2026 results pending. Analyst consensus is a $168.14 price target, with 39% buy ratings. News highlights Exxon's Permian Basin strength and warnings of potential oil price spikes to $160.
XOM offers value with a P/E of 20.68 and strong cash flow, but faces risks from volatile oil prices and declining margins. The dividend provides income, yet geopolitical tensions and energy transition pressures pose challenges. Upside depends on execution in the Permian and oil market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
